goserelin and Vulvar-Neoplasms

Aggressive angiomyxoma is a rare, locally infiltrative tumor, frequently occurring in female patients. Although wide local excision is considered standard therapy, radical surgery may be needed.. A 49-year-old woman presented with an aggressive angiomyxoma involving the vulva and bladder. Given the hormone receptor status and size of the tumor, the patient was initially treated with fulvestrant and goserelin acetate in an attempt to reduce the size of the mass. She was followed up at 1- to 3-month intervals; after 6 months of treatment, owing to increasing size of the mass and worsening symptoms, the decision was made to proceed with radical surgery.. Although a less radical surgical approach is preferred, radical surgery is possible for treatment of aggressive angiomyxoma when needed.

Topics: Antineoplastic Agents, Hormonal; Diagnosis, Differential; Estradiol; Female; Fulvestrant; Goserelin; Humans; Middle Aged; Myxoma; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vulvar Neoplasms

Aggressive angiomyxoma is a variant of myxoid neoplasms of the female pelvic soft parts. The term "aggressive" refers to the tumor's locally infiltrative and recurrent nature because distant metastases are rare.. A 25-year-old woman presented with a 9-month history of an asymptomatic, polypoid mass arising from the right anterior labium minus. Histopathological and radiological examinations were consistent with a diagnosis of aggressive angiomyxoma. The patient was treated with a GnRH agonist followed by surgical excision.. We highlight the novel use of a GnRH agonist as a neoadjuvant to surgery in aggressive angiomyxoma to shrink the tumor preoperatively and decrease surgical morbidity.

Topics: Adult; Antineoplastic Agents, Hormonal; Female; Goserelin; Humans; Myxoma; Neoadjuvant Therapy; Neoplasm Invasiveness; Treatment Outcome; Vulvar Neoplasms

Aggressive angiomyxoma (AA) is a vulvovaginal mesenchymal neoplasm with a marked tendency to local recurrence but which usually does not metastasise. Most cases exhibit positive immunohistochemical staining with oestrogen receptor (ER) and, or, progesterone receptor (PR).. We report a case of AA which exhibited positive immunohistochemical staining with ER and in which radiological examination following resection showed extensive residual tumour. The patient was commenced on gonadotropin-releasing hormone (GnRH) agonist therapy which resulted in complete radiological remission with replacement by scar tissue. The patient is currently maintained on a GnRH agonist.. The present case, together with several others reported in the literature, suggests that GnRH agonists may be of value in managing cases of AA, either primary or recurrent, which are not amenable to surgical excision. These agents may also be used to effect a reduction in size, so that more conservative surgery can be undertaken.

Topics: Adult; Antineoplastic Agents, Hormonal; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Myxoma; Receptors, Estrogen; Vulvar Neoplasms